KYGEVVI FDA approval date

The FDA approved KYGEVVI on 3 Nov 2025.

FDA approval date
3 Nov 2025

Drug identity has not yet been verified against registry records

Also recorded as DOXECITINE; DOXRIBTIMINE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2025-11-03DayKYGEVVIFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA219792", "applicant_as_listed_by_fda": "UCB INC", "brand_names": ["KYGEVVI"], "active_ingredients": ["DOXECITINE", "DOXRIBTIMINE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20251103", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026